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elanoma is associated with DNA dam-
age and genomic alterations caused
by ultraviolet light. In 2012, as part of
efforts to better understand the causes of mela-
noma, researchers at the Broad Institute, the
Dana-Farber Cancer Institute and a number of
other institutes reported the results of whole
genome sequencing of 25 human metastatic
melanomas (Berger et al., 2012). This analysis
discovered an average of 97 structural rear-
rangements of the genome per tumor, and
some 9,653 mutations of various types in 5,712
genes. A number of known melanoma onco-
genes were identified, including BRAFV600E (in
64% of tumors) and mutated NRAS (36%). The
analysis also found that a significant fraction of
tumors contained rearrangements and mutations
of a gene called PREX2, and experiments con-
firmed that cancer-associated mutations of
PREX2 promoted the growth of human mela-
noma cells in mice.
It has been known for a number of years that
PREX2 is a GTP/GDP exchange factor that inhib-
its a tumor suppressor protein called PTEN, and
that this process can promote tumorigenesis by
activating the PI3K signaling pathway
(Fine et al., 2009; Hodakoski et al., 2014;
Figure 1A). More recently it has been shown
that PTEN can inhibit PREX2, and that this can
stop tumor cells invading tissue by preventing
the activation of an enzyme called RAC
(Mense et al., 2015). Moreover, cancer-associ-
ated mutations in PREX2 disrupt these mutual
inhibition processes: mutated PREX2 can still
inhibit PTEN, but PTEN cannot inhibit mutated
PREX2 (Mense et al., 2015; Figure 1B). All this
work supports the conclusion that the over-
expression of PREX2 can increase PI3K-depen-
dent tumor growth (Fine et al., 2009), and that
mutated PREX2 promotes tumorigenesis by
increasing RAC-dependent invasiveness
(Mense et al., 2015).
As part of the Reproducibility Project: Cancer
Biology, Chroscinski et al. published a Regis-
tered Report which explained in detail how they
would seek to replicate selected experiments
from Berger et al. (Chroscinski et al., 2014).
The results of these experiments have now been
published as a Replication Study
(Horrigan et al., 2017).
The original paper by Berger et al. contained
two major conclusions. First, PREX2 was identi-
fied as a frequently mutated gene in human mela-
noma. The Reproducibility Project did not
attempt to replicate this finding, but subsequent
studies have reported the frequency of PREX2
mutations in human melanoma (Hodis et al.,
2012; Krauthammer et al., 2012;
Marzese et al., 2014; Ni et al., 2013;
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Turajlic et al., 2012), including meta-analysis of
241 melanomas (Xia et al., 2014). Second, muta-
tion of PREX2 can accelerate human melanoma
growth. The Reproducibility Project did attempt
to replicate the mouse xenograft studies that
support this second conclusion.
Berger et al. expressed six different mutated
PREX2 proteins in TERT-immortalized human
melanoma cells. These cells were transplanted
into immuno-deficient mice. Control studies
were performed using cells expressing either
wild-type PREX2 or green fluorescent protein
(GFP). Kaplan-Meier analysis demonstrated that
most of the mice injected with cells expressing
wild-type PREX2 or GFP exhibited tumor-free
survival for more than ten weeks. In contrast,
cancer-associated mutations in PREX2 signifi-
cantly reduced tumor-free mouse survival (Fig-
ures 3B and S6 of Berger et al.). The work of
Berger et al. supported the conclusion that can-
cer-associated PREX2 mutations can promote
the growth of human melanoma cells.
Attempts to replicate these xenograft experi-
ments were confounded by a serious technical
problem. The tumors grew rapidly in the control
experiments (the median time for tumor-free
survival was one week) and any differences in
tumor-free survival for the controls and the mice
injected with cells expressing mutated PREX2
were not statistically significant (Horrigan et al.,
2017). Consequently, no conclusions could be
drawn concerning the possible contribution of
PREX2 mutations to melanoma growth.
This Replication Study represents a cautionary
tale concerning the impact of biological variabil-
ity on experimental design. While strenuous
efforts were made to precisely copy the experi-
mental conditions employed in the original
study, the xenografts in the Replication Study
behaved in a fundamentally different way to
those in the original study. The mechanistic basis
for the observed differences is unclear. Presum-
ably, there was a difference in the melanoma
cells and/or the mice. Although the cells were
obtained from the same source, small differen-
ces in culture conditions or passage history
could have contributed to differences between
the studies. Similarly, although the mice were
obtained from the same source, housing the ani-
mals in a different facility may have contributed
to differences between the studies.
A key lesson to be drawn from this experi-
ence is that biological variability is a critical fac-
tor in experimental design. Pilot studies to
Figure 1. The roles of PREX2 and PTEN. (A) PREX2 (blue) is a GTP/GDP exchange factor that activates a GTPase
called RAC. PTEN (brown) is a lipid phosphatase that suppresses tumors by inhibiting PI3K signaling (not shown).
The interaction of PREX2 and PTEN (via their DHPH and CAT domains respectively) suppresses the catalytic
activity of both. (B) Cancer-associated mutations in PREX2 (or C-terminal truncation of PREX2, as shown here) do
not interfere with its ability to activate RAC or its ability to inhibit PTEN. However, PTEN is unable to inhibit
mutated PREX2. Therefore mutations in PREX2 can lead to cancer by increasing both RAC and PI3K signaling.
PREX2: phosphatidylinositol-3,4,5-triphosphate-dependent RAC exchange factor 2. PTEN: phosphatase and tensin
homolog. RAC: RAS-related C3 botulinum toxin substrate.
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explore biological variation would have allowed
this Replication Study to be redesigned to inject
fewer melanoma cells and thus delay tumor
growth. Biological variability means, therefore,
that direct replication of a reported study might
not always be the best way to assess reproduc-
ibility in certain fields.
Questions remain concerning the role of
PREX2 mutations in cancer. It is established that
PREX2 can be mutated in melanoma and pan-
creatic ductal adenocarcinoma (Berger et al.,
2012; Waddell et al., 2015), and that cancer-
associated PREX2 mutations can promote both
tumorigenesis in vivo (Lissanu Deribe et al.,
2016) and tumor cell invasiveness (Mense et al.,
2015). However, wild-type PREX2 can also pro-
mote tumor growth by suppressing PTEN activ-
ity and increasing PI3K signaling (Fine et al.,
2009). There is a clear need for further mecha-
nistic studies to explore the role of PREX2 and
mutations of PREX2 in cancer.
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